The global adrenal crisis management market, valued at USD 3.3 million in 2023, is projected to grow at a CAGR of 6.7% over the forecast period from 2023 to 2033, reaching an estimated value of USD 6.31 million by 2033. The market’s expansion is attributed to a rising prevalence of adrenal insufficiency, technological advancements in emergency medical care, and increasing awareness of adrenal crisis—a critical condition that requires prompt medical intervention.
Adrenal crisis management involves immediate treatment to address potentially life-threatening complications arising from adrenal insufficiency, a condition in which the adrenal glands produce insufficient levels of hormones like cortisol. Cortisol is essential for managing the body’s stress response, and its deficiency can lead to severe health risks during an adrenal crisis.
The market’s projected growth highlights the increased prioritization of adrenal crisis management by healthcare providers, pharmaceutical companies, and emergency response units. With continued research and development, the adrenal crisis management market is set to benefit patients by improving rapid-response therapies, ultimately enhancing survival rates and quality of life for individuals at risk.
Availability of treatments contributing to adrenal crisis management market
- Intravenous (IV) Hydrocortisone: IV hydrocortisone is the most common treatment for adrenal crisis. It is administered directly into a vein, allowing for rapid absorption into the bloodstream to replace the missing cortisol hormone.
- Intramuscular (IM) Hydrocortisone: IM hydrocortisone can be given when IV administration is not possible, such as in an emergency situation. It is injected into a muscle and can provide some relief from adrenal crisis symptoms, but it may not be as effective as IV administration.
- Oral Corticosteroids: Once the initial crisis has been treated, oral corticosteroids, such as prednisone or dexamethasone, may be prescribed to continue the replacement therapy and prevent future crises.
- Fluid Replacement Therapy: In severe cases, fluid replacement therapy may be necessary to address dehydration and restore electrolyte balance. Monitoring and Supportive Care: Patients with adrenal crisis may require close monitoring and supportive care, such as oxygen therapy, blood pressure monitoring, and electrolyte replacement, depending on the severity of their symptoms.
Market Competition
Key players in the adrenal crisis management are Eton Pharmaceuticals, Antares Pharma, Takeda Pharmaceutical Company Limited, Sandoz International GmbH, Pfizer Inc., Bristol-Myers Squibb Company, Merck KGaA, Mallinckrodt Pharmaceuticals, Mylan Pharmaceutical AG and Medtronic
- Sandoz is involved in research and development efforts related to endocrine disorders, including adrenal insufficiency. The company is focusing on developing new treatments for adrenal insufficiency and improved management of adrenal crisis.
- Pfizer is actively involved in researching and developing treatments for adrenal insufficiency, which is the underlying condition that can lead to adrenal crisis. One example of their research efforts in this area is the development of a new long-acting glucocorticoid therapy for the treatment of adrenal insufficiency.
Key Companies Profiled
- Eton Pharmaceuticals
- Antares Pharma
- Takeda Pharmaceutical Company Limited
- Sandoz International GmbH
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Merck KGaA
- Mallinckrodt Pharmaceuticals
- Mylan Pharmaceutical AG
- Medtronic Plc.
Key Segments Profiled in the Adrenal Crisis Management Industry Survey
Diagnosis Method:
- Blood Test
- ACTH Stimulation Test
- Insulin-induced Hypoglycaemia Test
- Imaging Test
Treatment Method:
- Oral Cortisone
- Hydrocortisone
- Fludrocortisone Acetate
- Intravenous Injections
- Corticosteroids
- Saline Solution
- Sugar (Dextrose)
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube